Lumen Bio Reports Positive Phase 2 Results for LMN-201

Seattle, Washington, USA, October 21, 2026

LMN-201 Demonstrates Improved Global Cure Rates

The Phase 2 REPREVE trial evaluated LMN-201 in patients diagnosed with CDI who received standard-of-care antibiotic treatment. The study enrolled 45 participants across its two parts, including 23 participants in the randomized, placebo-controlled Part B cohort. In Part B, participants received either LMN-201 or placebo alongside standard antibiotics, with treatment continuing during and after antibiotic therapy to improve initial treatment outcomes and prevent subsequent infection recurrence. Global cure, which combines successful initial treatment with protection against recurrence, was observed in 10 of 12 patients receiving LMN-201, compared with four of 11 patients receiving placebo. This represented a 47-percentage-point difference between the groups and was statistically significant under the trial’s prespecified Bayesian statistical analysis plan. The findings suggest that LMN-201 may offer benefits beyond standard antibiotic treatment alone. However, the randomized comparison involved a small number of participants, and larger studies will be needed to confirm the magnitude and reliability of the observed treatment effect.

Sixfold Reduction in C. difficile Recurrence

A key finding was the reduction in CDI recurrence, which can lead to repeated antibiotic courses, hospitalisation and additional complications. In the randomized Part B cohort, recurrence occurred in 9.1% of patients treated with LMN-201 compared with 55.6% receiving placebo, both alongside standard-of-care antibiotics. Lumen described this as an approximately sixfold reduction in recurrence. The company also reported that LMN-201 reduced primary cure failure by more than 50% relative to standard-of-care treatment alone, although this secondary endpoint did not reach statistical significance. These results are clinically relevant because CDI can recur after initial antibiotic treatment, particularly when the normal intestinal microbiome remains disrupted. Repeated infections can increase the burden on patients and healthcare systems. LMN-201 is intended to address this challenge through an oral combination of three toxin-binding proteins and an antibacterial enzyme, designed to target disease-causing toxins and the bacterium itself. The investigational therapy is delivered in capsules and is intended for use with and following standard antibiotic treatment.

Oral Biologic Shows Encouraging Safety Profile

Lumen reported that LMN-201 was well tolerated in the Phase 2 trial, with adverse-event rates similar to placebo and consistent with the underlying infection and initial antibiotic treatment. The company reported no drug-related serious adverse events or deaths. LMN-201 is manufactured using Lumen’s proprietary spirulina-based GMP production platform, which uses engineered spirulina to produce the biologic components. The company believes this manufacturing approach could support scalable production of oral biologic medicines. The investigational treatment’s capsule-based administration may also offer practical advantages compared with approaches requiring infusion or more complex administration. Nevertheless, the current results remain preliminary, and further clinical evaluation is required to establish safety and efficacy in larger patient populations.

The findings are scheduled for presentation at IDWeek 2026 in Washington, DC, on October 24, providing an opportunity for infectious disease specialists to review the trial data. CDI remains an important healthcare-associated infection, and recurrent cases continue to create substantial clinical and economic burdens. While the REPREVE results offer encouraging evidence for LMN-201, the treatment remains investigational and is not approved for routine clinical use. Further research will be essential to determine whether these results can be reproduced and translated into improved patient outcomes.

Source: Lumen Bioscience press release